Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia (NCT07365462)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.
Who can join: Review the eligibility criteria below.
Location: Neurocrine Clinical Site — Bryant, Arkansas
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Neurocrine Clinical Site — Bryant, Arkansas
- Neurocrine Clinical Site — Chino, California
- Neurocrine Clinical Site — Fountain Valley, California
- Neurocrine Clinical Site — Huntington Beach, California
- Neurocrine Clinical Site — Long Beach, California
- Neurocrine Clinical Site — Temecula, California
- Neurocrine Clinical Site — Torrance, California
- Neurocrine Clinical Site — Boca Raton, Florida
- Neurocrine Clinical Site — Bonita Springs, Florida
- Neurocrine Clinical Site — Hialeah, Florida
- Neurocrine Clinical Site — Miami, Florida
- Neurocrine Clinical Site — Orange City, Florida
- Neurocrine Clinical Site — Tampa, Florida
- Neurocrine Clinical Site — Marietta, Georgia
- Neurocrine Clinical Site — Lincoln, Nebraska
- Neurocrine Clinical Site — Beachwood, Ohio
- Neurocrine Clinical Site — Fort Worth, Texas
- Neurocrine Clinical Site — Houston, Texas
📞 Contact the Study Coordinator
Phone: (877) 641-3461
Email: medinfo@neurocrine.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Tardive Dyskinesia
- Studying Patterns in Patient Engagement Among Tardive Dyskinesia Patients — San Francisco, California
- Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities — Cleveland, Ohio
Explore by condition: All Tardive Dyskinesia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.